Therapy Optimization in Multiple Sclerosis 

Study Title

Therapy Optimization in Multiple Sclerosis (MS)

Teva Identifier

PM032

ClinicalTrials.gov Identifier

NCT00819000

Study Status

Completed

Trial Condition(s)

Multiple Sclerosis

Interventions

Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria
neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years and older

Trial Duration

12/01/2008 - 01/01/2013

Study Type

Observational